Segantii Capital Management’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Segantii Capital Management’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-100,000	Closed	-$1.01M	–	302
2023 Q1	$1.01M	Hold	100,000	–	–	0.04%	179
2022 Q4	$998K	Hold	100,000	–	–	0.04%	205
2022 Q3	$971K	Hold	100,000	–	–	0.03%	265
2022 Q2	$969	Hold	100,000	–	–	0.02%	257
2022 Q1	$975K	Hold	100,000	–	–	0.03%	273
2021 Q4	$981K	Hold	100,000	–	–	0.03%	225
2021 Q3	$983K	Buy	+100,000	New	+$988K	0.03%	199

Other funds holding DALS

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Segantii Capital Management's DALS Position: Q2 2023 in Review

Segantii Capital Management sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q2 2023, closing a stake of 100,000 shares — an estimated $1.01M sold.

Segantii Capital Management first reported a position in DALS in Q3 2021 and held it in 7 quarters. The position peaked at $1.01M in Q1 2023. 50 funds tracked by Wall St. Rank hold DALS as of Q2 2023.

Segantii Capital Management reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Segantii Capital Management sold 100,000 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q2 2023, an estimated $1.01M.
Segantii Capital Management first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q3 2021 and held it in 7 quarters.
Segantii Capital Management's DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $1.01M in Q1 2023.
50 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q2 2023.

Based on Segantii Capital Management's 13F filing for Q2 2023, filed 2 Aug 2023.